

## Title Page

### **Title of article**

Genetic Testing for Gynaecological Cancer

### **Authors**

Faiza Maryam Gaba, \*Ranjit Manchanda

1. Faiza Maryam Gaba MBBS, MRCOG

Clinical Research Fellow in Gynaecological Oncology

Barts Cancer Institute, Queen Mary University of London, Charterhouse Square,  
London, EC1M 6BQ

[faizagaba@nhs.net](mailto:faizagaba@nhs.net)

Telephone 07815607390

2. \*Ranjit Manchanda MD, MRCOG, PhD

Clinical Senior Lecturer, Consultant Gynaecological Oncologist

Barts Cancer Institute, Queen Mary University of London, Room 4, Basement, Old  
Anatomy Building, Charterhouse Square, London, EC1M 6BQ

[r.manchanda@qmul.ac.uk](mailto:r.manchanda@qmul.ac.uk)

Fax- 0203 594 2792

\* Corresponding author

## Abstract

The traditional family-history approach to genetic testing involves taking a detailed three generation family-history from both sides of the family, ethnicity, type of cancer, age of onset and death. Testing for BRCA1/BRCA2 mutations is offered at a  $\geq 10\%$  combined BRCA1/BRCA2 probability. Risk models such as the Manchester scoring system, BOADICEA, BRCAPRO can be used to calculate BRCA1/BRCA2 probability. High-risk women identified should be referred to a regional genetics service for genetic counselling and testing. The Amsterdam-Criteria-2 have been traditionally used to identify Lynch Syndrome (caused by a mismatch repair gene (MLH1/MSH2/MSH6/PMS2) mutation). Molecular (immunohistochemistry and Microsatellite instability) analysis of tumour tissue is now established as an initial step, with genetic testing undertaken for protein deficient or MSI unstable tumours. This is offered for those fulfilling Bethesda criteria and recently for all colorectal cancer cases <60 years. BRCA1/BRCA2 testing is recommended for all non-mucinous invasive epithelial ovarian cancers irrespective of family-history (10-20% have a BRCA1/BRCA2 mutation). This is being undertaken by non-genetics clinicians. A population-based approach to genetic testing identifies 50% more carriers at risk. It has been extensively investigated in the Ashkenazi-Jewish population and found to be extremely cost-effective in this community. This is expected to lead to change in guidelines in the future.

## Keywords

BRCA, genetic testing, risk prediction, ovarian cancer, breast cancer, endometrial cancer, Lynch Syndrome, high risk

## Genetic Testing for Gynaecological Cancer

### **Introduction**

The traditional approach to genetic testing for high penetrance gynaecological cancer gene mutations has been driven by family history (FH). This involves testing affected individuals from high-risk families through specialist cancer genetics clinics following intensive face-to-face genetic counselling. It requires both the individual patient as well as the clinical practitioner to be aware of the FH, appreciate the risk/significance of the FH and to act on it. The usually encountered hereditary gynaecological cancer syndromes include hereditary breast and/or ovarian cancer syndrome, Lynch Syndrome (or Hereditary Non-Polyposis Colorectal Cancer – HNPCC), Cowden’s Syndrome and Peutz–Jeghers syndrome.

### **Hereditary breast and/or ovarian cancer**

Autosomal dominant mutations in the BRCA1/BRCA2 genes account for most of the known hereditary risk of ovarian cancer. Women carrying BRCA1/BRCA2 genes have an 18-40% risk of ovarian cancer and 45-65% risk of breast cancer (higher risk estimates are obtained from data analysed from cancer genetics clinics which are uncorrected for ascertainment). Additionally, newer moderate penetrance genes (ovarian cancer risks 5%-9%) like the RAD51C, RAD51D and BRIP1 have been recently identified and validated risk estimates published. In the general population- around 1:300 – 1:400 individuals carry a BRCA1/BRCA2 mutation. In certain populations called founder populations (such as Ashkenazi Jews), BRCA1/BRCA2 mutations occur more frequently. 1:40 Ashkenazi Jewish individuals carry one of the three common BRCA1/BRCA2 mutations called founder mutations.

Over the years, a number of risk assessment models have been developed and modified. Models vary widely with respect to the data used to derive them, the study design, level of detail of FH, risk factors and the specifics of genetic transmission patterns included. Hence, each model has strengths and weaknesses dependent upon population characteristics, methodology, underlying assumptions and the statistical tools used to create them. Models are generally two types: Empirical and Mendelian. Descriptive FH variables are used to develop Empirical models, typically using logistic regression. These models are more straightforward to implement/use and can readily incorporate other non-genetic risk factors. A widely used example is the Manchester Scoring System (MSS). A major drawback is that they cannot adequately deal with complex family histories and MSS cannot be used for Ashkenazi Jewish families.

Mendelian models use pedigree analysis and Mendelian rules of genetic inheritance to develop a genetic model for disease, usually based on Bayesian and other likelihood ratio analyses. They are able to account for complex family histories and provide individualised probabilities of carrying a mutation. BOADICEA (Cambridge, UK) and BRCAPRO (Bayes-Mendel, USA) are commonly used examples. The National Institute of Health and Care Excellence (NICE) recommend that BRCA1/BRCA2 testing be offered to those who have a 10% combined BRCA1/BRCA2 probability. This threshold of offering genetic testing in the UK was earlier 20% and was lowered to 10% in 2013.

Models commonly used in the UK to estimate BRCA1/BRCA2 probability are – MSS, BOADICEA, Tyrer Cuzick (UK), BRCAPRO. MSS is an easy to use table which provides scores for BRCA1 and BRCA2 mutations based on female/male breast cancers, ovarian cancers,

prostate and pancreatic cancers on the same side of the family. With the MSS, a combined score of 16 corresponds to the 10% testing threshold and a score of 20 to the 20% threshold. Table-1 provides easy to read risk criteria which have been adapted from criteria widely used to identify high risk women in the UKFOCSS national ovarian cancer screening trial and the London Cancer familial gynaecological cancer MDT (Barts Hospital, UCLH). Different FH testing criteria exist for Jewish and the non-Jewish general population given the significantly different BRCA1/BRCA2 prevalence estimates (criteria being more lax in the latter). Thus taking a detailed FH is critical to risk assessment for considering genetic testing. This should include history from both maternal and paternal sides of the family, spanning at least 3 generations (first and second degree relatives), ethnicity, age of onset of cancer, type of cancer and age of death. Both affected and unaffected relatives should be noted. High-risk women identified should be referred to a regional genetics service for genetic counselling and testing.

### **Lynch Syndrome (LS)**

LS is an autosomal dominant syndrome, the tumour spectrum of which comprises colorectal (60% risk), endometrial (40-60% risk) and ovarian (approximate 10% (4-20%) risk) cancers. Additionally it also includes gastric, small bowel, hepato-biliary, brain, ureteric and renal pelvic (upper urologic tract) cancers. It is caused by a mutation in one of the mismatch repair (MMR) genes: MLH1, MSH2, MSH6 and PMS2. The Amsterdam criteria-2 (AC-2) have been traditionally used to identify LS. AC-2 includes at least 3 relatives in the family with one of the LS cancers, all of whom should be related by a first degree relationship, the LS cancers should span at least 2 generations and one should be <50 years. The AC-2 criteria miss a number of mutation carriers. Hence more lax criteria called Revised Bethesda criteria have

been used to improve ascertainment by identifying colorectal cancer cases for molecular analysis (immunohistochemistry (IHC) and Microsatellite instability (MSI)) as an initial step, with genetic testing undertaken for IHC protein deficient or MSI unstable tumours. IHC/MSI testing for all colorectal cancer cases <60 years is now recommended as an unselected approach increases carrier deification and is cost-effective. IHC & MSI analysis for 'all' EC cases is more effective at identifying MMR carriers/LS than Bethesda/AC-2 criteria alone, which miss 12-30%/ 55-70% of carriers respectively. Although IHC and MSI testing for endometrial cancer cases have been recommended by some guidelines to better ascertain individuals for genetic testing for MMR mutations, this is not yet common practice in the UK. However, this is likely to change going forward. Such an approach of unselected testing if implemented for epithelial ovarian cancers would also be able to identify 1-2% additional LS carriers. However, this is not yet part of routine practice and the cost-effectiveness of this approach has not been evaluated.

### **Systematic Epithelial Ovarian Cancer Case Series BRCA1/BRCA2 Testing**

Around 10%-20% of non-mucinous epithelial ovarian cancers have mutations in the BRCA1/BRCA2 genes. Around half of these would not be identified by the traditional FH based testing. NHS England and NICE guidelines now recommend BRCA1/BRCA2 testing for all women with non-mucinous high grade invasive epithelial ovarian cancer. This is gradually being implemented across the UK. In addition to predictive testing of unaffected family members, an added advantage is access to PARP inhibitors for those who develop Platinum sensitive relapsed ovarian cancer. Different models of pre-test counselling have been followed for this: (a) traditional approach of face-to-face counselling by the genetics clinician/genetic counsellor in a specialist genetics clinic; (b) telephone counselling by the

genetics clinician/genetic counsellor in a specialist genetics clinic; (c) Mainstreaming – non genetics clinician performing pre-test counselling after online training and post-test counselling undertaken by the regional genetics service; (d) GTEOC Cambridge model: genetics co-ordinated testing through local non-genetics clinicians.

**RAD51C, RAD51D and BRIP1 mutations:**

Genetic testing for these ovarian cancer gene mutations is not yet routine practice. However, a recent paper showed it would be cost-effective to offer risk reducing surgery at the levels of risk associated with these gene mutations. This provides clinical utility for genetic testing at these levels of risk, and suggests guidelines need changing in this respect.

**Cowden's Syndrome**

Autosomal dominant condition caused by PTEN gene mutations. It is associated with a 10-28% risk of endometrial cancer, 50% risk of breast cancer and 3-10% risk of thyroid cancer.

**Peutz-Jeghers Syndrome-**

This is caused by a mutation in the STK11/LKB1 gene. The condition is associated with an increased risk of cervical cancer (adenoma malignum), sex cord stromal ovarian tumours and breast cancer.

**Population based testing-**

FH based prediction models are only moderately effective at predicting the presence of a BRCA1/BRCA2 mutation and have a poor ability for predicting their absence. A large proportion (approximately 50%) of mutation carriers do not give a strong FH of cancer and

will not be detected by current clinical means. Given the significant benefits of screening/prevention available to mutation carriers, this questions the efficacy of the current FH based approach. These limitations can be overcome using a population-based approach to genetic testing.

A population testing approach for BRCA1/BRCA2 mutations has been extensively investigated in the Ashkenazi Jewish population and shown to identify 50% more people at risk, not detrimentally affect psychological health and can be highly cost-effective for the NHS, saving both lives and money. While there is strong evidence to suggest need for changing the clinical paradigm in this population to population based BRCA1/BRCA2 testing, this is yet to be implemented and is a matter of ongoing discourse.

**Table-1. Criteria to identify high risk families (London Cancer MDT)**

Volunteer/Proband should either have been affected by cancer or be a FDR of an affected family member
<b>Families with ovarian* or ovarian* and breast cancer</b>
<p>1) &gt;2 individuals with ovarian cancer (any age) who are first degree relatives (FDR).</p> <p>2) 1 ovarian cancer (any age) and 1 breast cancer &lt;50 who are FDR.</p> <p>3) 1 ovarian cancer (any age) and 2 breast cancers &lt;60 who are FDR.</p> <p>4) Breast cancer in volunteer/proband (&lt;45 years) and mother with both breast and ovarian cancer (in the same person).</p> <p>5) Breast cancer in volunteer/proband (&lt;40 years) and sister with both breast and ovarian cancer (in the same person).</p> <p>6) Criteria 1, 2 and 3 can be modified where paternal transmission is occurring i.e. families where affected relatives are related by second through an unaffected intervening male relative and there is an affected sister eligible.</p> <p><i>* History of tubal/primary peritoneal cancers may be considered equivalent to ovarian cancer.</i></p>
<b>Families with a known gene mutation</b>
7) The family contains an affected individual with a mutation in 1 of the known ovarian / endometrial cancer predisposing genes e.g. BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, PTEN, STK11/LKB1
<b>Lynch Syndrome / HNPCC Families</b>
<p>8) The family contains 3 or more individuals with a LS or HNPCC related cancer*, who are FDR and &gt;1 case is diagnosed before 50 years and the cancers affect &gt;1 generation.</p> <p><i>*LS or HNPCC related cancers include: colorectal, endometrial, small bowel, ureteric and renal pelvic cancers.</i></p>
<b>Families with only breast cancer</b>
<p>9) ≥4 breast cancers in the family (any ages)</p> <p>10) 3 breast cancers related by FDR:</p> <p>i) 1 &lt;30 years or</p> <p>ii) All &lt;40 years or</p> <p>iii) 1 male breast cancer (MBC) and 1 bilateral breast cancer.</p> <p>11) Breast cancer in volunteer/proband (&lt;50 years) and:</p> <p>i) Breast cancer in mother (age of onset being &lt;30 in one and &lt;50 years in the other) or</p> <p>ii) Bilateral breast cancer in mother (&lt;40 years onset) or</p> <p>iii) 1 MBC and 1 bilateral breast cancer.</p> <p>12) 2 MBC (1 &lt;40 years) in the family and proband is a FDR of 1 of them.</p>
<b>Families with Ashkenai Jewish (AJ) ancestry</b>
<p>13) Breast cancer (&lt;40 years) or bilateral breast cancer (first cancer &lt;50 years) in volunteer/proband irrespective of family history of cancer.</p> <p>14) Breast cancer in volunteer/proband (&lt;50 years) and 1 FDR with breast cancer (&lt;50 years) or ovarian cancer (any age) or MBC (any age).</p> <p>15) Breast cancer in volunteer/proband (&lt;60 years) and 1 FDR with breast cancer (&lt;40 years) or ovarian cancer (any age) or MBC (any age).</p> <p>16) 1 FDR with ovarian cancer (&lt;50 years).</p> <p>17) FDR with breast and ovarian cancer in the same woman (any age).</p> <p>18) 2 FDR with breast cancer (&lt;40 years).</p> <p>19) 2 MBC (&lt;60 years) in the family and proband is a FDR of 1 of them.</p> <p>20) Breast Cancer in self &lt;50 years or Ovarian cancer in self at any age</p>
<b>Women with non-mucinous invasive epithelial ovarian cancer (EOC)</b>

21) Women with invasive non mucinous EOC regardless of family history/ethnicity.
--

<b>Women with triple negative (TN) Breast Cancer &lt;50 years</b>
---

22) Women with TN Breast Cancer <50 years
---

## Further reading

1. Manchanda R, Jacobs I. Genetic screening for gynaecological cancer: where are we heading? *Future Oncol.* 2016 Jan;12(2):207-20.
2. Royal College of Obstetricians and Gynaecologists. Management of Women with a Genetic Predisposition to Gynaecological Cancers. Scientific Impact Paper No.48. 2015 Feb.
3. National Institute of Clinical Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164). 2013 Jun.
4. National Health Service England. Clinical Commissioning Policy: Genetic Testing for BRCA1 and BRCA2 Mutations. 2015 Jul.
5. Lancaster JM, Powell CB, Chen LM, Richardson DL, SGO Clinical Practice Committee. SGO Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predisposition. *Gynecol Oncol.* 2015 Sep;138(3):765.
6. Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I. Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing. *JNCI J Natl Cancer Inst* (2015) 107(1): dju380.
7. D G R Evans, F Laloo, A Cramer, E A Jones, F Knox, E Amir, A Howell. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. *J Med Genet* 2009;46:811–817. doi:10.1136/jmg.2009.067850